Previous 10 | Next 10 |
Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions PR Newswire Additional operational efficiencies and opportunities expected with the engagement of Potrero Hill Advisors Sandra Gardiner succeeds Rex Merchant as acting chief financial officer ...
NEW YORK, NY / ACCESSWIRE / February 14, 2023 / Sidoti & Company, LLC announces that its two spring conferences are now open for registration. The March Virtual Small-Cap Conference will take place on Wednesday and Thursday, March 22-23, 2023, and the May Virtual Micro-Cap Conference wil...
Anebulo Pharmaceuticals press release ( NASDAQ: ANEB ): Q2 GAAP EPS of -$0.15 misses by $0.04 . Cash was $16.4 million as of December 31, 2022. For further details see: Anebulo Pharmaceuticals GAAP EPS of -$0.15 misses by $0.04
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial results for the th...
Summary Anebulo pharmaceutical is a US small-cap ($80M market cap) biotech company that is developing a phase 2 asset for cannabis-related intoxication. ANEB-001 targets a cannabinoid intoxication; we do not believe the market potential for "acute intoxication" to be as lucrative as the...
Preliminary data showed ANEB-001 reduced effects of a 30 mg dose of THC Delayed dosing of ANEB-001 rapidly reversed pre-existing THC effects Full PK, PD, and safety data expected by end of 1Q2023 Company targeting an End of Phase 2A meeting with FDA in the first half of 20...
Anebulo Pharmaceuticals press release ( NASDAQ: ANEB ): Q1 GAAP EPS of -$0.11 misses by $0.01 . Cash was $19.2 million as of September 30, 2022. For further details see: Anebulo Pharmaceuticals GAAP EPS of -$0.11 misses by $0.01
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial result...
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), today announced t...
Anebulo Pharmaceuticals ( NASDAQ: ANEB ) will sell an aggregate of 2.3M shares and accompanying warrants to purchase up to 2.3M shares to certain institutional accredited investors through a private investment in public equity financing at $2.935 per share and accompanyin...
News, Short Squeeze, Breakout and More Instantly...
Anebulo Pharmaceuticals Inc. Company Name:
ANEB Stock Symbol:
NASDAQ Market:
Anebulo Pharmaceuticals Inc. Website:
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), has been awarded the first tranche of a two year cooperati...
CHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced it has reached a cooperation agreemen...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.2% to $126.57 on volume of 604,432,871 shares American Rebel Holdings Inc. (AREB) rose 152.5% to $0.76 on volume of 367,740,589 shares Sirius XM Holdings Inc. (SIRI) rose 1.0% to $2.93 on volume of 329...